Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service LAA occlusion & loop recorders cases in California: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (229 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 136 | 5,793 | 48% |
| 2020 | 128 | 5,322 | 50% |
| 2021 | 169 | 6,961 | 52% |
| 2022 | 187 | 8,093 | 53% |
| 2023 | 210 | 9,337 | 55% |
| 2024 | 227 | 10,060 | 56% |
| 2025 from claims | – | 12,512 11,483–13,238 | 56% |
| 2026 forecast | – | 13,797 12,139–15,922 | 56% |
| 2027 forecast | – | 15,142 12,944–18,044 | 56% |
| 2028 forecast | – | 16,617 13,865–20,346 | 56% |
| 2029 forecast | – | 18,235 14,893–22,868 | 57% |
| 2030 forecast | – | 20,009 16,030–25,642 | 57% |
Left atrial appendage closure and implantable loop recorders: an older, Medicare-heavy population. Professional codes (what the surgeon bills): CPT 33340, 33285; the hospital bills MS-DRG 273, 274, 317.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 19% of the cases CMS names in California; 120 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 53% inpatient hospital, 14% hospital outpatient, 2% surgery center, 31% office. The share outside the hospital has moved +2 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Surgery center | Office |
|---|---|---|---|---|
| 2026 · ~13,800 | ~7,400 | ~1,800 | ~310 | ~4,200 |
| 2027 · ~15,100 | ~8,300 | ~1,900 | ~340 | ~4,600 |
| 2028 · ~16,600 | ~9,100 | ~2,100 | ~380 | ~5,000 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: inpatient hospital about 55% (53% in 2025), hospital outpatient about 13% (14% in 2025).
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Arizona | 106 | 4,739+15%/yr | +15%/yr | 5.6 | 41% | 7,950 in 2030+9%/yr |
| Washington | 46 | 2,007+11%/yr | +11%/yr | 2.3 | 2% | 3,420 in 2030+9.3%/yr |
| Colorado | 39 | 1,871+12%/yr | +12%/yr | 3.3 | 4% | 4,220 in 2030+15%/yr |
| Idaho | 16 | 740+15%/yr | +15%/yr | 3.2 | 0% | 1,470 in 2030+12%/yr |
| Oregon | 19 | 718+9.3%/yr | +9.3%/yr | 1.5 | 5% | 1,330 in 2030+11%/yr |
| Utah | 21 | 682+17%/yr | +17%/yr | 2.7 | 16% | 1,130 in 2030+8.9%/yr |
| Nevada | 14 | 673+17%/yr | +17%/yr | 2.0 | 16% | 1,740 in 2030+17%/yr |
| New Mexico | 5 | 431+11%/yr | +11%/yr | 1.6 | 2% | 1,040 in 2030+16%/yr |
| Montana | 12 | 395+13%/yr | +13%/yr | 1.9 | 0% | 760 in 2030+11%/yr |
| Alaska | 4 | 103+2.1%/yr | +2.1%/yr | 0.8 | 39% | 120 in 2030+2.5%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Pacemaker, ICD & CRT implantation | 239 | 12,086−4.4%/yr | −4.4%/yr | 3.70.9× | 4% | 12,400 in 2030+0.5%/yr |
| EP ablation | 165 | 11,552+8.2%/yr | +8.2%/yr | 2.90.9× | 0% | 21,900 in 2030+11%/yr |
LAA occlusion & loop recorders in every state, and its device makers · Every procedure market in California · Every state · Compare with Arizona
Boston Scientific leads with 84% of company spending on these surgeons in 2025, +19 pts on 2024.
In 2025, 6 companies reported engagement with California’s surgeons worth $719K in consulting, speaking, meals and travel tied to these products, about $3,169 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 20 clearances and approvals in the category, 6 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.